Compare Starbucks Corp (SBUX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Starbucks Corp trades at $100 (market cap $114.05B), while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: Starbucks Corp pays a 2.48% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Starbucks Corp nearer its low. Which is the better fit depends on your goals.
| SBUX | XBI | |
|---|---|---|
Market Cap | $114.05B | — |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $108.55 | $169.55 |
52-Week Low | $78.46 | $93.43 |
Enterprise Value | $132.87B | — |
Dividend Yield | 2.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $102.01, down 2.35% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish momentum in moving averages but recent earnings beats in Q1 and Q2 2026 highlight operational progress. Revenue reached $37.18B in 2025, though net income margin compressed to 5.17%. Analyst consensus is a Buy with a $113.60 price target, but high P/E of 58.97 suggests premium valuation. Recent news emphasizes CEO Niccol's turnaround efforts and union-related legal developments.
The outlook balances earnings momentum against valuation concerns. Upside hinges on margin recovery and sustained comp sales growth, but risks include labor disputes, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic, with 47.46% of analysts rating Buy.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
